Development of tricalcium phosphate/amylopectin paste combined with recombinant human transforming growth factor beta 1 as a bone defect filler
✍ Scribed by Ongpipattanakul, Boonsri ;Nguyen, Tue ;Zioncheck, Thomas F. ;Wong, Rita ;Osaka, Gary ;DeGuzman, Leo ;Lee, Wyne P. ;Beck, L. Steven
- Publisher
- John Wiley and Sons
- Year
- 1997
- Tongue
- English
- Volume
- 36
- Category
- Article
- ISSN
- 0021-9304
No coin nor oath required. For personal study only.
✦ Synopsis
Tricalcium phosphate (TCP) was combined with that the model used was not a critical defect may account amylopectin to form a deliverable carrier paste for recombi-for the lack of superiority of the rhTGF- 1 -treated group over nant human transforming growth factor  1 (rhTGF- 1 ) in-the healing of the sham control. The in vivo pharmacokinetics tended for bone repair applications. Approximately 80% of of the growth factor evaluated in the same rabbit model rhTGF- 1 was released from the carrier within 24 h following suggested that rhTGF- 1 persisted intact at the defect site in vitro incubation in serum. Full biological activity was main-for more than 21 days. Gamma imaging and radioactivity tained, suggesting the growth factor was stable in this formu-recovery at defects administered to [ 131 I]-and [ 125 I]-labeled lation before and after in vitro release. In vivo efficacy also rhTGF- 1 , respectively, estimated the half-life of rhTGF- 1 was assessed, in comparison to a sham control group and a eliminated from the applied site to be 4-6 days. The present placebo-treated group, using a rabbit unilateral segmental report substantiates the potential of rhTGF- 1 and its carrier defect model (1 cm). Radiographs of defect sites taken at for treatment of bone defects. © 1997 John Wiley & Sons, scheduled intervals and the mechanical testing of treated Inc. J Biomed Mater Res, 36, 295-305, 1997. limbs at 56 days demonstrated a higher incidence of radiographic bone union, in concert with a stronger torque Key words: bone defect filler; transforming growth factorstrength, in the rhTGF- 1 -treated group compared to the  1 ; release kinetics; in vivo efficacy; pharmacokinetics placebo group. The short duration of the study and the fact *Present address: 1871 Orange Tree Lane, Mountain View, repair. 6,9 Purified TGF- 1 induces proliferation of os-CA 94040 teoblasts in vitro and induces the in vivo formation Correspondence to: T. Nguyen of bone. 11 Addition of recombinant human TGF- 1 (rhTGF- 1 ) to a nonhealing calvarial defect in rabbits induces a dose-dependent increase in bone formation